SCHEMBL2643121

SCHEMBL2643121

COc1ccc(CN2C(=O)c3ccccc3C2CCS(=O)(=O)Nc2nccs2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.44
HKDC1 Q2TB90 1/20 0.44
SCN1A P35498 2/20 0.44
SCN8A Q9UQD0 2/20 0.44
PKM P14618 3/20 0.43
USP2 O75604 2/20 0.40
RECQL P46063 2/20 0.40
TDP1 Q9NUW8 2/20 0.40
POLB P06746 1/20 0.40
PPARG P37231 1/20 0.40
BLM P54132 1/20 0.40
NCOA2 Q15596 1/20 0.40
NCOA1 Q15788 1/20 0.40
SCN9A Q15858 1/20 0.40
ALDH1A1 P00352 5/20 0.39
MAPT P10636 3/20 0.39
ALOX15 P16050 3/20 0.39
HSD17B10 Q99714 3/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
MAPK1 P28482 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2643460 0.79 KDM4E (0.48) KDM4EHKDC1POLBSCN9AMAPT
SCHEMBL1619278 0.76 MEN1 (0.49) KDM4EHKDC1PKMUSP2TDP1
SCHEMBL2643782 0.74 KDM4E (0.52) KDM4EHKDC1SCN9AMAPTMAPK1
SCHEMBL2644038 0.74 CASP3 (0.46) KDM4EHKDC1TDP1POLBMAPT
SCHEMBL2643292 0.74 KDM4E (0.49) KDM4EHKDC1SCN9AMAPTMAPK1
SCHEMBL2643610 0.73 HRH1 (0.55) KDM4EUSP2TDP1POLBALDH1A1
SCHEMBL2644660 0.73 KDM4E (0.53) KDM4EHKDC1MAPTMAPK1RAB9A
SCHEMBL9071628 0.73 KDM4E (0.47) KDM4EHKDC1POLBMAPTMAPK1
SCHEMBL2644601 0.72 KDM4E (0.51) KDM4EHKDC1POLBMAPTMAPK1
SCHEMBL2643348 0.72 KDM4E (0.54) KDM4EHKDC1MAPTMAPK1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8796313-B2 Substituted dihydroisoindolones as allosteric modulators of glucokinase JANSSEN PHARMACEUTICA N.V. (BE) 2014-08-05 US disclosed
US-8796313-B2 Substituted dihydroisoindolones as allosteric modulators of glucokinase JANSSEN PHARMACEUTICA N.V. (BE) 2014-08-05 US disclosed
US-8796313-B2 Substituted dihydroisoindolones as allosteric modulators of glucokinase JANSSEN PHARMACEUTICA N.V. (BE) 2014-08-05 US disclosed
US-20070099930-A1 Substituted Dihydroisoindolones As Allosteric Modulators of Glucokinase JANSSEN PHARMACEUTICA N.V. (BE) 2007-05-03 US disclosed
US-20070099930-A1 Substituted Dihydroisoindolones As Allosteric Modulators of Glucokinase JANSSEN PHARMACEUTICA N.V. (BE) 2007-05-03 US disclosed
US-20070099930-A1 Substituted Dihydroisoindolones As Allosteric Modulators of Glucokinase JANSSEN PHARMACEUTICA N.V. (BE) 2007-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070099930-A1 Substituted Dihydroisoindolones As Allosteric Modulators of Glucokinase GCK, GCKR, GPR119 KDM4E 1206/4885HKDC1 61/4885SCN1A 1771/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.